PMID- 15685301
OWN - NLM
STAT- MEDLINE
DCOM- 20050331
LR  - 20151119
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 21
IP  - 1
DP  - 2005 Jan
TI  - Cardiac troponin I, a possible predictor of survival in patients with stable 
      congestive heart failure.
PG  - 39-43
AB  - BACKGROUND: Cardiac troponin I (cTnI) has been validated as a sensitive and 
      specific marker of myocyte damage, and is elevated in some patients with 
      congestive heart failure. OBJECTIVE: To assess the relationship between elevated 
      levels of cTnI and survival in stable patients with congestive heart failure. 
      PATIENTS AND METHODS: It was assessed whether detectable serial levels of cTnI 
      were associated with mortality in 211 patients with stable, severe heart failure 
      at entry and one month into the Prospective Randomized Flosequinan Longevity 
      Evaluation (PROFILE) study. Of these patients, 66 also had measurements taken at 
      12 months. RESULTS: Patients were New York Heart Association (NYHA) class III 
      (n=197) or IV (n=14), with a baseline left ventricular ejection fraction of 
      22+/-7% (range 8% to 35%). Patients with a detectable level of cTnI at one month 
      had an increased mortality (OR 2.608 [95% CI 1.061 to 6.409]; P=0.037). The 
      association between mortality and detectable cTnI levels at baseline or 12 months 
      did not reach statistical significance. Patients with a cTnI level that rose or 
      remained elevated between baseline and one month had a higher mortality rate 
      (50%) than those in whom the cTnI level fell (9%) between baseline and one month 
      (P=0.025). In a multivariate model of survival that included sex, treatment, age, 
      left ventricular ejection fraction, NYHA class and creatinine, only detectable 
      levels of cTnI at one month were associated with survival (P=0.037). CONCLUSIONS: 
      cTnI is released in stable, chronic heart failure and is associated with a poor 
      prognosis, independent of other important risk factors. The risk is particularly 
      elevated when detectable cTnI levels rise or remain elevated over time.
FAU - Stanton, Eric B
AU  - Stanton EB
AD  - Division of Cardiology, McMaster University and St Joseph's Hospital, Hamilton, 
      Ontario. stantone@mcmaster.ca
FAU - Hansen, Mark S
AU  - Hansen MS
FAU - Sole, Michael J
AU  - Sole MJ
FAU - Gawad, Yehia
AU  - Gawad Y
FAU - Packer, Milton
AU  - Packer M
FAU - Pitt, Bertram
AU  - Pitt B
FAU - Swedberg, Karl
AU  - Swedberg K
FAU - Rouleau, Jean L
AU  - Rouleau JL
CN  - PROFILE investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Biomarkers)
RN  - 0 (Troponin I)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - *Cause of Death
MH  - Cohort Studies
MH  - Female
MH  - Heart Failure/blood/*diagnosis/*mortality
MH  - Heart Function Tests
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Survival Analysis
MH  - Troponin I/*blood
EDAT- 2005/02/03 09:00
MHDA- 2005/04/01 09:00
CRDT- 2005/02/03 09:00
PHST- 2005/02/03 09:00 [pubmed]
PHST- 2005/04/01 09:00 [medline]
PHST- 2005/02/03 09:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 2005 Jan;21(1):39-43.